Skip to main content

Table 4 Number (%) of patients with non-hematological adverse events by severity and relationship to study drug.

From: Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial

N = 95 Grade 1/2 Grade 3/4
Preferred term total related Total related
nausea 34(35.8) 26(27.4) 2(2.1) 1(1.1)
oedema 8(8.4) 8(8.4) 2(2.1) 1(1.1)
oedema peripheral 29(30.5) 23(24.1) -- --
oedema genital 1(1.1) 1(1.1) --  
Eyelid oedema 23(24.2) 23(24.2) -- --
Face oedema 6(6.3) 6(6.3) -- --
Periorbital edema 8(8.4) 8(8.4) -- --
Vomiting 12(12.6) 8(8.4) 5(5.3) 1(1.1)
Muscle cramp 17(17.9) 15(15.8) -- --
Muscle spasticity 2(2.1) 1(1.1) -- --
Diarrhea 25(26.3) 19(20.0) 1(1.1) 1(1.1)
Dermatitis allergic 1(1.1) 1(1.1) -- --
Rash 2(2.1) 1(1.1) -- --
Headache 8(8.4) 2(2.1) 1(1.1) 1(1.1)
Abdominal pain 24(25.3) 4(4.2) 3(3.2) --
Arthralgia 9(9.5) 2(2.1) 1(1.1) --